DGAT2 and metabolic dysfunction-associated steatotic liver disease: Since DGAT2 is currently tested as a new therapeutic target for treating MASLD/MASH,75,76 we further examined the expression of DGAT2 in our group of 262 individuals with obesity from the KOBS cohort with bulk RNA-seq data from both their adipose and liver tissues and liver histology-based assessment of their clinical MASLD status.